Bioxytran, Inc.
BIXT · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $3 | $2 | $5 |
| Gross Profit | $0 | -$3 | -$2 | -$3 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $103 | $350 | $34 |
| G&A Expenses | $159 | $116 | $149 | $859 |
| SG&A Expenses | $159 | $122 | $149 | $449 |
| Sales & Mktg Exp. | $0 | $6 | $0 | -$405 |
| Other Operating Expenses | $337 | $0 | $17 | $45 |
| Operating Expenses | $496 | $224 | $515 | $528 |
| Operating Income | -$496 | -$224 | -$515 | -$484 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $213 | $260 | -$838 | -$29 |
| Pre-Tax Income | -$283 | $35 | -$1,354 | -$512 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$283 | $35 | -$1,354 | -$512 |
| % Margin | – | – | – | – |
| EPS | -0.003 | 0 | -152.37 | -0.004 |
| % Growth | -900% | 100% | -3,809,150% | – |
| EPS Diluted | -0.003 | 0 | -152.37 | -0.004 |
| Weighted Avg Shares Out | 88,992 | 88,840 | 9 | 138,599 |
| Weighted Avg Shares Out Dil | 88,992 | 88,840 | 9 | 138,599 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $37 | $45 | $32 | $647 |
| Depreciation & Amortization | $4 | $3 | $2 | $3 |
| EBITDA | -$242 | $83 | -$1,320 | -$484 |
| % Margin | – | – | – | – |